Cytokinetics to Announce First Quarter Results on May 5, 2026
Cytokinetics (Nasdaq: CYTK) will report first quarter 2026 results on May 5, 2026 at 4:00 PM ET, followed by a senior management conference call at 4:30 PM ET to discuss financial results and business updates.
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) will report first quarter 2026 results on May 5, 2026 at 4:00 PM ET, followed by a senior management conference call at 4:30 PM ET to discuss financial results and business updates.
The call will be webcast simultaneously and an archived replay will be available on the company's investor website for six months.
Details
News Market Reaction – CYTK
On Apr 22, the first trading day after this news, CYTK closed 0.68% above the previous close.
Data tracked by StockTitan Argus for the Apr 22 session.
Key Figures
- Q1 2026 earnings date
- May 5, 2026
- Scheduled reporting date for first quarter results
- Earnings release time
- 4:00 PM ET
- Planned time for Q1 2026 results announcement
- Conference call time
- 4:30 PM ET
- Start time for Q1 2026 earnings conference call
- Webcast replay duration
- 6 months
- Archived replay availability via company website
- Year-end cash
- $1.22 billion
- Cash balance at end of 2025 (prior earnings release)
- 2025 revenue
- $88.0 million
- Full-year 2025 revenue from prior earnings report
- 2026 GAAP R&D+SG&A guidance (low end)
- $830 million
- Lower bound of 2026 operating expense guidance
- 2026 GAAP R&D+SG&A guidance (high end)
- $870 million
- Upper bound of 2026 operating expense guidance
Previous Earnings date Reports
-
Scheduled Q4 2025 earnings release and conference call timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.
The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com or directly at the following link: Cytokinetics Q1 2026 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics’ website for six months.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.